Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

Targeting of Hematologic Malignancies with PTC299, A Novel Potent Inhibitor of Dihydroorotate Dehydrogenase with Favorable Pharmaceutical Properties.

Cao L, Weetall M, Trotta C, Cintron K, Ma J, Kim MJ, Furia B, Romfo C, Graci JD, Li W, Du J, Sheedy J, Hedrick J, Risher N, Yeh S, Qi H, Arasu T, Hwang S, Lennox W, Kong R, Petruska J, Moon YC, Babiak J, Davis TW, Jacobson A, Almstead NG, Branstrom A, Colacino JM, Peltz SW.

Mol Cancer Ther. 2019 Jan;18(1):3-16. doi: 10.1158/1535-7163.MCT-18-0863. Epub 2018 Oct 23.

PMID:
30352802
2.

Identification of benzazole compounds that induce HIV-1 transcription.

Graci JD, Michaels D, Chen G, Schiralli Lester GM, Nodder S, Weetall M, Karp GM, Gu Z, Colacino JM, Henderson AJ.

PLoS One. 2017 Jun 28;12(6):e0179100. doi: 10.1371/journal.pone.0179100. eCollection 2017.

3.

PTC725, an NS4B-Targeting Compound, Inhibits a Hepatitis C Virus Genotype 3 Replicon, as Predicted by Genome Sequence Analysis and Determined Experimentally.

Graci JD, Jung SP, Pichardo J, Lahser F, Tong X, Gu Z, Colacino JM.

Antimicrob Agents Chemother. 2016 Nov 21;60(12):7060-7066. Print 2016 Dec.

4.

RNA virus population diversity, an optimum for maximal fitness and virulence.

Korboukh VK, Lee CA, Acevedo A, Vignuzzi M, Xiao Y, Arnold JJ, Hemperly S, Graci JD, August A, Andino R, Cameron CE.

J Biol Chem. 2014 Oct 24;289(43):29531-44. doi: 10.1074/jbc.M114.592303. Epub 2014 Sep 11.

5.

Identification of PTC725, an orally bioavailable small molecule that selectively targets the hepatitis C Virus NS4B protein.

Gu Z, Graci JD, Lahser FC, Breslin JJ, Jung SP, Crona JH, McMonagle P, Xia E, Liu S, Karp G, Zhu J, Huang S, Nomeir A, Weetall M, Almstead NG, Peltz SW, Tong X, Ralston R, Colacino JM.

Antimicrob Agents Chemother. 2013 Jul;57(7):3250-61. doi: 10.1128/AAC.00527-13. Epub 2013 Apr 29.

6.

Mutational robustness of an RNA virus influences sensitivity to lethal mutagenesis.

Graci JD, Gn├Ądig NF, Galarraga JE, Castro C, Vignuzzi M, Cameron CE.

J Virol. 2012 Mar;86(5):2869-73. doi: 10.1128/JVI.05712-11. Epub 2011 Dec 21.

7.

High-throughput screening uncovers a compound that activates latent HIV-1 and acts cooperatively with a histone deacetylase (HDAC) inhibitor.

Micheva-Viteva S, Kobayashi Y, Edelstein LC, Pacchia AL, Lee HL, Graci JD, Breslin J, Phelan BD, Miller LK, Colacino JM, Gu Z, Ron Y, Peltz SW, Dougherty JP.

J Biol Chem. 2011 Jun 17;286(24):21083-91. doi: 10.1074/jbc.M110.195537. Epub 2011 Apr 15.

8.

Therapeutically targeting RNA viruses via lethal mutagenesis.

Graci JD, Cameron CE.

Future Virol. 2008 Nov;3(6):553-566.

9.

HIV type-1 latency: targeted induction of proviral reservoirs.

Graci JD, Colacino JM, Peltz SW, Dougherty JP, Gu Z.

Antivir Chem Chemother. 2009;19(5):177-87. Review.

PMID:
19483266
10.

Lethal mutagenesis of picornaviruses with N-6-modified purine nucleoside analogues.

Graci JD, Too K, Smidansky ED, Edathil JP, Barr EW, Harki DA, Galarraga JE, Bollinger JM Jr, Peterson BR, Loakes D, Brown DM, Cameron CE.

Antimicrob Agents Chemother. 2008 Mar;52(3):971-9. doi: 10.1128/AAC.01056-07. Epub 2008 Jan 7.

11.

Effects of introduction of hydrophobic group on ribavirin base on mutation induction and anti-RNA viral activity.

Moriyama K, Suzuki T, Negishi K, Graci JD, Thompson CN, Cameron CE, Watanabe M.

J Med Chem. 2008 Jan 10;51(1):159-66. Epub 2007 Dec 8.

PMID:
18067241
12.

Lethal mutagenesis of poliovirus mediated by a mutagenic pyrimidine analogue.

Graci JD, Harki DA, Korneeva VS, Edathil JP, Too K, Franco D, Smidansky ED, Paul AV, Peterson BR, Brown DM, Loakes D, Cameron CE.

J Virol. 2007 Oct;81(20):11256-66. Epub 2007 Aug 8.

13.

Synthesis of a universal 5-nitroindole ribonucleotide and incorporation into RNA by a viral RNA-dependent RNA polymerase.

Harki DA, Graci JD, Edathil JP, Castro C, Cameron CE, Peterson BR.

Chembiochem. 2007 Aug 13;8(12):1359-62. No abstract available.

14.

Synthesis and antiviral activity of 5-substituted cytidine analogues: identification of a potent inhibitor of viral RNA-dependent RNA polymerases.

Harki DA, Graci JD, Galarraga JE, Chain WJ, Cameron CE, Peterson BR.

J Med Chem. 2006 Oct 19;49(21):6166-9.

15.

Mechanisms of action of ribavirin against distinct viruses.

Graci JD, Cameron CE.

Rev Med Virol. 2006 Jan-Feb;16(1):37-48. Review.

PMID:
16287208
16.

Challenges for the development of ribonucleoside analogues as inducers of error catastrophe.

Graci JD, Cameron CE.

Antivir Chem Chemother. 2004 Jan;15(1):1-13. Review.

PMID:
15074710
17.

Quasispecies, error catastrophe, and the antiviral activity of ribavirin.

Graci JD, Cameron CE.

Virology. 2002 Jul 5;298(2):175-80. Review.

18.

Synthesis and antiviral evaluation of a mutagenic and non-hydrogen bonding ribonucleoside analogue: 1-beta-D-Ribofuranosyl-3-nitropyrrole.

Harki DA, Graci JD, Korneeva VS, Ghosh SK, Hong Z, Cameron CE, Peterson BR.

Biochemistry. 2002 Jul 23;41(29):9026-33.

PMID:
12119016

Supplemental Content

Loading ...
Support Center